After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
The latest first-in-human trial initiations include projects licensed in by Gilead and Context.
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
The UK company buys IRDx for $1bn.
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
Scorpion's STX-478 becomes at least the third shot Lilly has taken at PI3Kα.
